Potential Applications for Targeted Gene Therapy to Protect Against Anthracycline Cardiotoxicity: JACC: CardioOncology Primer

Anthracyclines are associated with risk of significant dose-dependent cardiotoxicity. Conventional heart failure therapies have neither ameliorated declining cardiac function nor addressed the underlying cause. Gene therapy may confer long-term cardioprotection by rendering the heart resistant to an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kok, Cindy Y., MacLean, Lauren M., Ho, Jett C., Lisowski, Leszek, Kizana, Eddy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Primers in Cardio-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702812/
https://www.ncbi.nlm.nih.gov/pubmed/34988473
http://dx.doi.org/10.1016/j.jaccao.2021.09.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8702812/
https://www.ncbi.nlm.nih.gov/pubmed/34988473
http://dx.doi.org/10.1016/j.jaccao.2021.09.008

Ejemplares similares